Cell Therapy Technologies Market worth $8.0 billion | MarketsandMarkets™

The global cell therapy technologies market is projected to reach USD 8.0 billion by 2027 from USD 4.0 billion in 2022, at a CAGR of 14.6% during the forecast period. Market growth is driven mainly by increasing research in regenerative medicine along with stem cell research, cancer research, and cell biology research. Moreover, cell therapy technologies are extensively used in research centers and research institutes for life science and biopharmaceutical R&D. Such factors are fueling the market growth.

Key Market Players

The global cell therapy technologies market is consolidated. The prominent players operating in this market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US). Product launches and acquisitions are the key growth strategies undertaken by these companies to maintain their positions in the market.

To know about the assumptions considered for the study download the pdf brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978

Thermo Fisher Scientific

Thermo Fisher Scientific offers a complete and integrated portfolio of solutions and services for clinical science, laboratory research, and analysis. It operates in four business segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. Its Life Sciences Solutions segment offers a wide range of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as the diagnosis of diseases. The company offers products in the cell therapy technologies market through its Life Sciences Solutions and Laboratory Products and Services business segments.

Thermo Fisher has a wide customer base, which includes pharmaceutical and biotechnology companies, hospitals and clinical diagnostic laboratories, universities, research institutions, government agencies, and environmental and process control industries. The company operates in more than 180 countries across North America, Europe, Asia, the Middle East, Africa, and Latin America.

Merck KGaA

Merck operates through three business segments, namely, Healthcare, Life Science, and Performance Materials. The Life Science segment offers life science products and services for research and diagnostic purposes. Merck offers products in the cell therapy technologies market through its Life Science segment. This segment further operates through three divisions, namely, Process Solutions, Research Solutions, and Applied Solutions.

Merck operates in over 70 countries across North America, South America, Latin America, Europe, Asia, Africa, and the Middle East.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=213334978

Danaher Corporation

Danaher Corporation operates through three strategic segments—Environmental and Applied Solutions, Life Sciences, and Diagnostics. The Diagnostics segment offers a wide range of products through its key brands—SCIEX, Beckman Coulter, Leica Biosystems, Leica Microsystems, Radiometer, and Cepheid. Beckman Coulter and Cytiva, subsidiaries of Danaher Corporation, cater to the cell therapy technologies market. Beckman develops, manufactures, and markets products in automation, diagnostics, and chemistry. Cytiva, which was formerly a part of GE Healthcare Life Sciences, offers cell therapy development solutions, such as cell processing, cell banking, and point-of-care technologies. The company operates in Europe, North America, and the Asia Pacific. It has 212 manufacturing and distribution facilities worldwide

Recent Developments

• Thermo Fisher Scientific launched the first T-cell medium designed specifically for allogeneic cell therapy workflows.
• Danaher acquired the Biopharma business from General Electric Company's Life Sciences division. The acquisition has led to the formation of a new business named Cytiva, a standalone operating company within Danaher's Life Sciences segment.

Cell Therapy Technologies Market Advantages:

1. High-end cell therapy technologies help enhance the efficacy of the treatments, thereby improving patient outcomes.

2. Cell therapy technologies are used to develop personalized treatments for a wide range of diseases such as cancer, Parkinson’s, Alzheimer’s and diabetes.

3. Cell therapy technologies enable cost-effective treatments due to the reduced cost of drug development and clinical trial costs.

4. Cell therapy technologies provide better quality of life for patients as they are less invasive and more effective than conventional treatments.

5. Cell therapy technologies help in reducing the risk of drug resistance and adverse effects.

6. Cell therapy technologies enable the development of more specific cell-based therapies, which are more targeted and efficient than conventional treatments.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=213334978

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Article source: https://article-realm.com/article/Health-Fitness/Exercise/39631-Cell-Therapy-Technologies-Market-worth-8-0-billion-MarketsandMarkets.html